The science desk for regenerative aesthetics
We explain the biology of extracellular vesicles and the treatments built on it, we grade each claim against a published vocabulary, and we say plainly where the evidence is thin. No product is endorsed. No figure is published that we cannot source.
Every claim gets a panel
The panel states the claim, the proposed mechanism, what has actually been shown and at what level, the main confounders, and a grade from a fixed vocabulary. Every panel ends with the study that would change our assessment, named in advance, so that when we move a grade it can be checked against what we said we were waiting for.
A commercially available exosome preparation applied to skin improves dermal collagen in humans.
- Proposed mechanism
- Vesicles cross the disrupted skin barrier, are taken up by dermal fibroblasts, and deliver cargo that increases matrix synthesis.
- What has been shown
- Each link in that chain has been examined separately in laboratory systems. Delivery of intact vesicles to human dermis at a functional dose has not been demonstrated so far as we can establish, and clinical studies generally cannot separate the preparation from the barrier-disrupting procedure used to apply it.
- Highest level reached
- In vitro only
- Main confounders
- Microneedling is an effective treatment in its own right. Vehicle occlusion on permeable skin. Unblinded appearance endpoints. Unidentified active principle, so dose cannot be defined.
GradeEARLY, UNREPLICATED
What would change thisA randomised, blinded trial comparing needling plus the preparation against needling plus an identical vehicle without the vesicle fraction, with a pre-specified objective endpoint assessed beyond the resolution of procedural effects.
The full vocabulary, including what each grade requires, is published at the grading vocabulary. Grades cannot be bought. See the rate card.
Two checklists you can take to a supplier
The sections explain the biology and the evidence. These two pages are built to be used while you are holding somebody’s paperwork: each step names the standard behind it, and each says what it cannot establish. Both are informational review aids. Neither certifies, approves or endorses anyone, and neither is a compliance determination.
Exosome cancer risk evidence: a sourced checklist
Six steps for testing whether a cancer risk claim about a vesicle product identifies the material, uses relevant controls and supports its conclusion, against MISEV2023, ICH S2(R1) and ARRIVE 2.0.
Use the checklistInstrumentLondon regenerative aesthetics: standards checklist
The regulatory route, premises controls, supplier records and data handling a London service should be able to show you, with the source named for each and statutory duties kept apart from procurement preferences.
Use the checklistSectionReading the evidence
How to judge the studies a supplier offers: controls and blinding, endpoints that mean something, what sample size buys you, and why translation failure is normal rather than suspicious.
Read the sectionWhat this publication is
Exosomal Therapy is an independent science desk covering extracellular vesicles and the regenerative aesthetics treatments built on them. It is not owned by, funded by or affiliated with any clinic, supplier, distributor or manufacturer, it treats none of them as a client, and it endorses no product. It earns from clearly labelled listings and one labelled sponsor line at the foot of the briefing, and neither buys coverage, a grade, a correction or silence. Nothing here is medical advice or a treatment recommendation, and no article decides whether any person should receive anything. What we will and will not publish is set out in our editorial standards, how we earn in full on the about page, and what we refuse at any price on the rate card. Corrections are made on the page and dated: if something here is wrong, tell the desk.
Vesicle science
What an extracellular vesicle is, how one is made, what it carries, and what a cell does with it.
What an exosome actually is, and how the word is used commercially
The biological definition of an exosome, the reason specialists prefer the term extracellular vesicle, and why the commercial usage is broader.
ReadVesicle scienceHow extracellular vesicles are made
Biogenesis of exosomes and plasma membrane vesicles, why the two routes are hard to separate, and what that means for any product claim.
ReadVesicle scienceWhat is inside an extracellular vesicle
Proteins, lipids and nucleic acids in vesicle cargo, why cargo lists are easy to produce, and why a list is not a mechanism.
ReadVesicle scienceHow vesicles are taken up by cells
Endocytosis, membrane fusion and the fate of vesicle contents inside a recipient cell, and why a fluorescent signal is not proof of functional delivery.
ReadThe regenerative family
Polynucleotides, platelet preparations, growth factors, conditioned media, skin boosters and biostimulators, treated as one family with different logic.
What regenerative actually means as a scientific claim
Regeneration, repair and remodelling are different biological outcomes. Most aesthetic treatments described as regenerative produce the second or third.
ReadThe regenerative familyPolynucleotides: what the molecule is
What polynucleotide injectables are made of, the proposed mechanisms, and how the evidence for them compares with the confidence of the marketing.
ReadThe regenerative familyPRP and PRF: what actually differs
Platelet rich plasma and platelet rich fibrin, how preparation changes composition, and why heterogeneous protocols make the literature hard to pool.
ReadThe regenerative familyGrowth factors in topical and injectable products
What growth factors are, why size and stability limit topical delivery, and what a growth factor claim on a label does and does not establish.
ReadFour rules we hold to
We invent no figures
Where an effect size, sample size or percentage would normally appear, we describe the shape of the evidence and say the figure is not one we can source. A number we cannot trace is worse than no number, because it travels.
We rank no clinics
Assessing clinical practice needs records, outcomes and governance data we do not have. Any ranking we published would rank marketing. Where we name a provider we say we have not assessed them.
We do not publish before and after images
We cannot verify the lighting, position, expression or processing behind any such image. An unverifiable image is not evidence, and presenting one as evidence would undo the rest of the site.
Money cannot move a grade
Paid listings and a labelled newsletter sponsor line are how this publication earns. Neither buys coverage, a grade, a correction or silence. What we refuse at any price is published.
Regulation
The UK position, the borderline products question, human tissue law, and why jurisdictions diverge.
The UK position on exosome products, stated carefully
What can and cannot be said about the regulatory status of exosome products in the UK, which framework applies, and where the position is genuinely unsettled.
ReadRegulationTopical after microneedling is a different question
Why applying a preparation to deliberately breached skin sits awkwardly between topical use and administration, and what is settled versus unsettled.
ReadRegulationBorderline products and the MHRA
How the medicines definition works through presentation and function, why marketing claims can change a product's classification, and how to apply the test yourself.
ReadSourcing and manufacture
Cell source, culture, isolation, characterisation and batch control. The part that decides what is in the vial.
Why the cell source matters more than the brand
Cell type, donor, tissue of origin and passage number change what a preparation contains. None of these are visible on a box.
ReadSourcing and manufactureIsolation methods compared
Ultracentrifugation, size exclusion chromatography, tangential flow filtration and precipitation, and what each keeps and discards.
ReadSourcing and manufactureWhat a real specification sheet shows
The measurements that constitute proper characterisation of a vesicle preparation, and how to tell a specification from a description.
ReadReading the evidence
Study design, sample size, controls, endpoints, conflicts of interest, preprints, and why translation failure is normal.
In vitro, in vivo, in human
What each level of evidence can establish, why the gaps between them are where most claims fail, and how to place a study on the ladder.
ReadReading the evidenceSample size and what it buys you
Why small studies produce unreliable estimates, what statistical power means in practice, and why a small positive study should not raise your confidence much.
ReadReading the evidenceControls, blinding and the split face design
Why the control arm decides what a study can conclude, what blinding protects against, and the specific strengths and limits of split face designs in aesthetics.
ReadReading the evidenceEndpoints that mean something
Surrogate versus clinical endpoints, why appearance scales are harder than they look, and how endpoint choice decides what a study can claim.
ReadThe newest entries
The two most recent pieces on this publication, newest first.
London regenerative aesthetics: standards checklist
A sourced checklist for reviewing regulatory status, premises controls, supplier documents, records and data handling in London.
Read10 September 2026Storage and reconstitution of vesicle products: procedural risks
How vesicle products should be stored and reconstituted on arrival, the risks of incorrect handling, and what supplier documentation certifies or omits.
Read10 September 2026Can Exosomes Cause Cancer? A Sourced Evidence Checklist
A sourced checklist for assessing whether a vesicle product's cancer-risk evidence identifies the material, tests relevant hazards and supports its conclusion.
Read10 September 2026How to Read a Clinic’s Exosome Explainer
A buyer’s framework for separating sourced exosome definitions from evidence, product specifications and UK regulatory analysis.
Read10 September 2026FDA RF Microneedling Safety Communication: What It Says
A source-led reading of the FDA's 2025 RF microneedling safety communication, its limits, and its relevance for UK device assessment.
ReadThe science briefing
One email a fortnight. What was published in extracellular vesicle and regenerative aesthetics research, what it actually showed, and which claims moved on our grading scale. Written for people who read the methods section.
No spam, unsubscribe in one click. We never pass your address to a third party. See privacy.
Sponsor slot Each issue carries one labelled sponsor line at the foot. Sponsorship buys that line and nothing else. It cannot influence an evidence grade, a correction, or whether a claim is covered. Rate card and refusals.